Jacobs Levy Equity Management
KROS icon

Jacobs Levy Equity Management’s Keros Therapeutics KROS Stock Holding History

Jacobs Levy Equity Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.8M Sell
706,071
-62,354
-8% -$963K 0.03% 343
2025
Q4 		$15.6M Buy
768,425
+161,336
+27% +$2.83M 0.06% 243
2025
Q3 		$9.6M Buy
607,089
+82,749
+16% +$1.22M 0.04% 307
2025
Q2 		$7M Buy
+524,340
New +$7.08M 0.03% 369

Other funds holding KROS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Jacobs Levy Equity Management's KROS Position: Q1 2026 in Review

Jacobs Levy Equity Management reduced its Keros Therapeutics (KROS) stake by 8.1% in Q1 2026, selling an estimated $963K and leaving 706,071 shares worth $7.8M. The position accounts for 0.03% of the portfolio, ranked #343.

Jacobs Levy Equity Management first reported a position in KROS in Q2 2025 and has held it in 4 quarters since. The position peaked at $15.6M in Q4 2025. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Jacobs Levy Equity Management held 706,071 shares of Keros Therapeutics worth $7.8M as of Q1 2026.
  • Jacobs Levy Equity Management sold 62,354 Keros Therapeutics shares in Q1 2026, an estimated $963K.
  • Keros Therapeutics made up 0.03% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #343 holding.
  • Jacobs Levy Equity Management first reported a position in Keros Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Jacobs Levy Equity Management's Keros Therapeutics position peaked at $15.6M in Q4 2025.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.